Lonza Group AG
OTC:LZAGF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
557.8467
737.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.3B CHF |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.2T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.2B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
154.9B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81.3T KRW |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.2B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.6B EUR |
Loading...
|
|
| US |
|
Illumina Inc
NASDAQ:ILMN
|
22.7B USD |
Loading...
|
Market Distribution
| Min | -57 027.8% |
| 30th Percentile | 1.3% |
| Median | 7.2% |
| 70th Percentile | 13.7% |
| Max | 3 663.7% |
Other Profitability Ratios
Lonza Group AG
Glance View
Amidst the serene valleys and bustling innovation hubs of Switzerland, Lonza Group AG has carved an indelible niche in the dynamic world of life sciences. Established in 1897, this stalwart of the biotech and pharmaceutical industry seamlessly blends traditional Swiss precision with cutting-edge scientific inquiry. Originally a chemical company, Lonza has reinvented itself over the years, today standing as a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and nutrition sectors. From delivering small molecules and complex biologics to pioneering innovations in cell and gene therapy, Lonza's versatile and expansive portfolio underscores its core strength: fostering the seamless transition from early-stage research to full-scale manufacturing. This unique capability leverages a vast network of state-of-the-art facilities and expert talent, enabling Lonza to nurture groundbreaking therapies from concept through to market readiness. The secret to Lonza's business model lies in its adept mix of contract development and manufacturing (CDMO) services, enabling it to partner with a diverse clientele ranging from nimble biotechs to giant pharmaceutical firms. This breadth of collaboration adds a layer of stability and scale to its operations, generating revenue through long-term manufacturing agreements and comprehensive development programs. Lonza thrives on its ability to tailor its offerings, providing customized support at various stages of a drug’s lifecycle — from early discovery to commercial supply. Furthermore, their expansion into high-growth areas such as personalized medicine and biotechnology bolsters their competitive edge while aligning with market demand trends. This strategic alignment, coupled with a relentless pursuit of operational excellence and innovation, propels Lonza's enduring legacy as both a powerhouse and a partner in forging the future of medicine.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Lonza Group AG is 10.3%, which is below its 3-year median of 12.6%.
Over the last 3 years, Lonza Group AG’s Net Margin has decreased from 53.3% to 10.3%. During this period, it reached a low of 8.6% on Jun 30, 2024 and a high of 53.3% on Jun 30, 2022.